Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC).[2][3][4][5] Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms.[6] It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.[7][8][9]
^"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
^ ab"Xalkori- crizotinib capsule". DailyMed. Archived from the original on 9 October 2021. Retrieved 18 April 2021.
^ ab"Xalkori EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 19 April 2021. Retrieved 18 April 2021.
^"Drug Approval Package: Xalkori Capsules (crizotinib) NDA #202570". U.S. Food and Drug Administration (FDA). 27 September 2011. Archived from the original on 7 April 2021. Retrieved 18 April 2021.
^"Summary Review for Regulatory Action" (PDF). U.S. Food and Drug Administration (FDA). 26 August 2011. Archived (PDF) from the original on 6 April 2021. Retrieved 19 April 2021.
^Clinical trial number NCT00585195 for "A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer" at ClinicalTrials.gov
^Forde PM, Rudin CM (June 2012). "Crizotinib in the treatment of non-small-cell lung cancer". Expert Opinion on Pharmacotherapy. 13 (8): 1195–201. doi:10.1517/14656566.2012.688029. PMID 22594847. S2CID 23715951.
^Roberts PJ (2013). "Clinical use of crizotinib for the treatment of non-small cell lung cancer". Biologics: Targets and Therapy. 7: 91–101. doi:10.2147/BTT.S29026. PMC 3643289. PMID 23671386.
^Sahu A, Prabhash K, Noronha V, Joshi A, Desai S (April 2013). "Crizotinib: A comprehensive review". South Asian Journal of Cancer. 2 (2): 91–7. doi:10.4103/2278-330X.110506. PMC 3876666. PMID 24455567.
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC)...
years, compared with 8% of patients treated with the standard of care (crizotinib). Lorlatinib must not be combined with strong inducers (i.e. activators)...
implications on the response of the tumour and prognosis of the patient. Crizotinib (also a ROS1 and c-MET inhibitor) was approved in Aug 2011 by the US FDA...
treatment of adults with ALK‑positive advanced NSCLC previously treated with crizotinib. In the United States, it is indicated for the treatment of people with...
been increasing. Recently, the small molecule tyrosine kinase inhibitor, crizotinib, was approved for the treatment of patients with metastatic NSCLC whose...
responses to crizotinib while 1 patient previously treated with a corticosteroid, prednisone, continued to have progressive disease on crizotinib; and 3) 6...
adenocarcinoma Glioblastoma multiforme Anaplastic thyroid cancer Xalkori (crizotinib), produced by Pfizer, was approved by the FDA for treatment of late stage...
Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK inhibitor, but has since had its usage expanded to serve...
in hyperactive ALK protein, which can be treated with ALK inhibitors crizotinib, or its successors alectinib, brigatinib, and ceritinib. Those treated...
(Toceranib), was also approved for cancer in dogs, and the ALK inhibitor Crizotinib also grew out of a SUGEN program. In October 2006, the company announced...
kinase inhibitors, e.g. FDA approved tofacitinib ALK inhibitors, e.g. crizotinib Bcl-2 inhibitors (e.g. FDA approved venetoclax, obatoclax in clinical...
started at Sugen also contributed to the development of the ALK inhibitor crizotinib (Xalkori), FDA-approved for NSCLC in 2011. Sugen also generated extensive...
Global Information
(what is this?) (verify)